Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Redx Raises Funds And Remains Independent

Yesod Bid 'Substantially Undervalued' UK Biotech

Executive Summary

Redx's takeover talks with a consortium led by controversial biotech veteran Sam Waksal, who was jailed for five years over his role in the ImClone stock scandal in 2003, have been terminated but the UK biotech has received a financial lifeline from Redmile and Sofinnova.

You may also be interested in...



Redx Cashes In Cancer Program With Jazz Pact

Shares in the UK biotech tripled to a 52-week high after it announced the sale of its pan-RAF inhibitor program to Jazz that could eventually be worth around $200m.

Revamped Redx’s New CEO Says Porcupine Inhibitor Trials 'Now On Track'

After regulatory talks, revamped Redx gets green light to resume clinical study of RXC004 in patients with advanced solid tumors, while sister porcupine inhibitor RXC006 is set to enter IPF trials in 2020, the biotech's CEO tells Scrip.

Redx Ready To Get Back To The Clinic After Tough Year

CEO Lisa Anson has brought "a sense of urgency, focus and realism" to Redx since she took over five months ago, says its chairman, and the firm has high hopes for its investigational porcupine inhibitors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel